Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHAT | P28329 | 2/20 | 0.43 |
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | EP300 | Q09472 | 3/20 | 0.42 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.40 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | NAA40 | Q86UY6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24913480 | 0.90 | KRAS (0.45) | POLB | |
| SCHEMBL21786830 | 0.89 | CHAT (0.45) | CHATNAA50AURKAEP300KAT5 | |
| SCHEMBL24913567 | 0.89 | P2RX1 (0.45) | CHATNAA50AURKAEP300KAT5 | |
| SCHEMBL21786896 | 0.87 | CHAT (0.46) | CHATNAA50AURKAEP300KAT5 | |
| SCHEMBL21786889 | 0.87 | P2RX3 (0.47) | CHATNAA50AURKAEP300KAT5 | |
| SCHEMBL21786834 | 0.86 | POLG (0.40) | POLB | |
| SCHEMBL24913298 | 0.84 | P2RX3 (0.49) | CHATAURKAP2RX1P2RX3P2RX2 | |
| SCHEMBL21787115 | 0.84 | P2RX3 (0.49) | CHATAURKAP2RX1P2RX3P2RX2 | |
| SCHEMBL24913349 | 0.84 | POLB (0.46) | POLB | |
| SCHEMBL24913450 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, NUDT1 | CHAT 3414/4885NAA50 580/4885AURKA 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.